Theriva Biologics (TOVX) Change in Accured Expenses (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Change in Accured Expenses of -$172000.0 for Q1 2026, down 158.31% year-over-year from $295000.0 in Q1 2025, and down 126.79% quarter-over-quarter from $642000.0 in Q4 2025.
Theriva Biologics (TOVX) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Change in Accured Expenses for 17 consecutive years, with -$172000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 158.31% year-over-year to -$172000.0; the TTM figure through Mar 2026 stood at -$1.2 million (down 177.12% YoY), while the FY2025 annual figure was -$744000.0, down 112.57% from the prior year.
- Change in Accured Expenses slipped to -$172000.0 in Q1 2026 per TOVX's latest filing, from $642000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.6 million in Q4 2023 and bottomed at -$1.1 million in Q4 2024.
- Historically, Change in Accured Expenses has averaged -$3705.9 across 5 years, with a median of -$172000.0 in 2026.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 1616.67% — and 2023, when it slumped 7833.33%.
- Theriva Biologics' Change in Accured Expenses stood at -$538000.0 in 2022, then soared by 397.21% to $1.6 million in 2023, then plunged by 167.23% to -$1.1 million in 2024, then surged by 159.72% to $642000.0 in 2025, then sank by 126.79% to -$172000.0 in 2026.
- Business Quant data shows TOVX's Change in Accured Expenses at -$172000.0 in Q1 2026, $642000.0 in Q4 2025, and -$959000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | 368,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 368,000.00 |
| Jun 30, 2026 | 368,000.00 |
| Mar 31, 2026 | -172,000.00 |
| Mar 31, 2026 | -172,000.00 |
| Dec 31, 2025 | 642,000.00 |
| Dec 31, 2025 | 642,000.00 |
| Sep 30, 2025 | -959,000.00 |
| Sep 30, 2025 | -959,000.00 |
| Jun 30, 2025 | -722,000.00 |
| Jun 30, 2025 | -722,000.00 |
| Mar 31, 2025 | 295,000.00 |
| Mar 31, 2025 | 295,000.00 |
| Dec 31, 2024 | -1.08 Mn |
| Dec 31, 2024 | -1.08 Mn |
| Sep 30, 2024 | 1.26 Mn |
| Sep 30, 2024 | 1.26 Mn |
| Jun 30, 2024 | -920,000.00 |
| Jun 30, 2024 | -920,000.00 |
| Mar 31, 2024 | 382,000.00 |
| Mar 31, 2024 | 382,000.00 |